Vitamin D Receptor Immunoexpression in Benign and Malignant Prostate Tumors

R. N. A. Ginting; Dwi Rita Anggraini; M. S. Sitorus

doi:10.3889/oamjms.2020.5148

Authors

R. N. A. Ginting Department of Histology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Dwi Rita Anggraini Department of Anatomy, Faculty of medicine, Universitas Sumatera Utara, Medan, Indonesia
M. S. Sitorus Department of Anatomy, Faculty of medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.5148

Keywords:

Vitamin D Receptor, prostate tumors, benigna, malignant

Abstract

BACKGROUND: Prostate cancer is a major health concern of men. Vitamin D can modulate innate or adaptive immune responses. The anticancer and anti-inflammatory effects of Vitamin D are mediated through gene transcription by Vitamin D receptor (VDR), including angiogenesis and tumor cell invasion. Targeted therapy in carcinoma prostate such as is as calcitriol is an alternative therapy for better treatment outcome.

METHODS AND MATERIALS: We investigated VDR immunoexpression in benign prostatic hyperplasia (BPH) and prostate adenocarcinoma. The cross-sectional study, categorical analysis of 60 paraffin blocks consist of 30 samples diagnosed as BPH, and 30 samples of prostate adenocarcinoma were divided three grading groups based on Patterns of Gleason: low, moderate, and high grade. Immunostaining was used to evaluate the VDR immunoexpression by histoscore.

RESULTS: The results showed that strong expression of VDR was 40% in BPH and 33.33% in prostate adenocarcinoma (p = 0.961). The strong expression of VDR in low, moderate, and high grade was 10%, 3.33%, and 20%, respectively. Statistically, there is no significant different (p = 0.906).

CONCLUSION: Positive immunoexpression of VDR affected the differentiation of prostatic adenocarcinoma.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Globocan 2012 Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://www. lglobocan.iarc fr. [Last accessed on 2014 Nov 19].

American Cancer Society. Cancer Facts and Statistics 2014. Georgia, United States: American Cancer Society; 2014.

Cabarkapa S, Perera M, McGrath S, Lawrentschuk N. Prostate cancer screening with prostate-specific antigen: A guide to the guidelines. Prostate Int. 2016;4(4):125-9. https://doi.org/10.1016/j.prnil.2016.09.002 PMid:27995110

Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684-700. https://doi.org/10.1038/nrc2196 PMid:17721433

Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011;29(17):2378-85. https://doi.org/10.1200/jco.2010.30.9880 PMid:21537045

Aminah H, Erida Y, Yulianti H, Hassan AH. Correlation of Vitamin D receptor (VDR) expression with differentiation staging and grading in colorectal adenocarcinoma. MKB. 2016;48(2):123-8. https://doi.org/10.15395/mkb.v48n2.387.

Gupta D, Vashi PG, Trukova K, Lis CG, Lammersfeld CA. Prevalence of serum Vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp Ther Med. 2011;2(2):181-93. https://doi.org/10.3892/etm.2011.205 PMid:22977487

Wang Y, Zhu J, DeLuca HF. Where is the Vitamin D receptor? Arch Biochem Biophys. 2012;523(1):123-33. https://doi.org/10.1016/j.abb.2012.04.001 PMid:22503810

Moch H, Humphrey PA, Ulbright TU, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: International Agency for Research on Cancer; 2016.

Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, et al. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2765-72. https://doi.org/10.1158/1055-9965.epi-09-0490 PMid:19789368

Erida Y, Aminah H, Yulianti H, Hernowo BS Vitamin D Receptor (VDR) and phosphatidylinositol 3-kinase (PI3K) independently affected colorectal adenocarcinoma differentiation. Indones J Clin Pharm. 2015;4(4):264-74.

Gurumurthy D, Maggad R, Patel S. Prostate carcinoma: Correlation of histopathology with serum prostate specific antigen. Sci J Clin Med. 2015;4(4-1):1-5. https://doi.org/10.11648/j.sjcm.s.2015040401.11

Jackson LA, McGrowder DA, Lindo RA. Prostate specific antigen and gleason score in men with prostate cancer at a private diagnostic radiology centre in Western Jamaica. Asian Pac J Cancer Prev. 2012;13(4):1453-6. https://doi.org/10.7314/apjcp.2012.13.4.1453 PMid:22799347

Pike JW, Meyer MB. The Vitamin D receptor: New paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am. 2010;39(2):255-69. https://doi.org/10.1016/j.ecl.2010.02.007 PMid:20511050

Gocek E, Studzinski GP. Vitamin D and differentiation in cancer. Crit Rev Clin Lab Sci. 2009;46(4):190. https://doi.org/10.1080/10408360902982128 PMid:19650715

Pereira F, Larriba MJ, Munoz A. Vitamin D and colon cancer. Endocr Relat Cancer. 2012;19(3):R51-71. https://doi.org/10.1530/erc-11-0388 PMid:22383428